TABLE 3.
Trials at the University of Minnesota
| Type of trial | Agent | Cohort | Primary outcome | Clinical Trials.gov identifier |
|---|---|---|---|---|
| Chemoprevention | Celecoxib | Preneoplasia | Leukoplakia Reduction | Not listed |
| Exam adjunct | Tolonium Chloride | Post resection | Recurrence detection | Not listed |
| Phase IIA | Pioglitazone | Preneoplasia | Leukoplakia Reduction | NCT00099021 |
| Phase IIB | Pioglitazone | Preneoplasia | Leukoplakia Reduction | NCT00951379 |
| Phase IIa | Metformin | Preneoplasia | Leukoplakia Reduction | NCT02581137 |
| Window of opportunity | Actoplus Met XR (pioglitazone metformin) | Preresection oral cancer | Cell proliferation marker reduction (Ki 67) | NCT02917629 |